Fabric Genomics

No. Fabric Genomics is a commercial health-IT company that sells AI-powered genomic interpretation software to clinical labs and hospitals. There is no disclosed AUM, no reported investment portfolio, and no public indication of family-office or fund-manager status. Institutional allocators evaluating the firm as a GP or asset manager are likely looking at the wrong entity.

Fabric sells a software platform that takes raw DNA sequencing reads from instruments like Illumina sequencers and applies machine learning to identify clinically relevant genetic variants. The output is a draft clinical report that a lab director or geneticist can review, finalize and sign. The platform supports whole-genome, whole-exome and targeted gene-panel analysis and is marketed to clinical labs operating under regulated diagnostic workflows.

Fabric's platform is designed for clinical use, which means it must comply with medical-device software standards (it undergoes 510(k) clearance as a Class II device by the FDA) and adhere to clinical reporting guidelines from organizations like the American College of Medical Genetics. Research tools typically lack the regulatory documentation, audit trails, and validated variant-classification pipelines that clinical reimbursement requires.

Fabric's customers are primarily hospital molecular pathology labs, reference laboratories, and academic medical centers that run high-volume clinical sequencing operations. The platform targets institutions that need to scale whole-exome or whole-genome testing for programs such as newborn rare-disease screening and hereditary-cancer panels, where manual variant curation teams become a throughput bottleneck.

No. The public record contains no information about the firm's capitalization structure, founder wealth, or any affiliated investment vehicles. As a venture-backed operating company with no disclosed AUM, it does not meet the typical definition of a family office or asset manager and therefore has no wealth-origin disclosure obligation.